ABOS · Acumen Pharmaceuticals, Inc. · Earnings Calls, Transcripts & Webcasts
$0.19
-0.01 (-3.52%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Oct 26, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least 12 months following the date of issuance of our unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Oct 26, 2026
Market Cap
$13.49M
Shares
72.33M
Volume · Nov 20
2.71M
Avg daily vol (3M)
2.7M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Acumen Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Acumen Pharmaceuticals, Inc. (ABOS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-26
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Confident tone
Phase III and subcutaneous strategy
Clinical trial execution
Safety and biomarkers
Net income
−$25.37M
Diluted EPS
$-0.35
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 16, 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 16, 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Acumen Pharmaceuticals, Inc. (ABOS) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Confident tone
Top-line ALTA-2/altitude readout expectations
Mechanism and target (oligomers vs plaque)
Sobbernatug (SabernaTug) safety/tolerability differentiation
Net income
−$32.72M
Diluted EPS
$-0.45
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-14
Acumen Pharmaceuticals, Inc. (ABOS) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Confident tone
EBD / JCR Pharmaceuticals partnership
IgG2 safety differentiation vs IgG1 antibodies
Altitude AD Phase II readout
Net income
−$20.74M
Diluted EPS
$-0.33
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Confident tone
EBD program with JCR
Altitude AD Phase II readout
AD field sentiment and unmet need
Net income
−$25.14M*
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Positive tone
ACU234 Next-Generation Antibody
EBD Program with JCR Pharmaceuticals
Competitive Landscape / GLP-1 Readouts
Net income
−$26.45M
Diluted EPS
$-0.44
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Positive tone
JCR Pharmaceuticals partnership (EBD program)
ARIA safety profile
Strategic portfolio expansion
Net income
−$40.95M
Diluted EPS
$-0.68
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Confident tone
Phase 2 ALTITUDE-AD enrollment completion and timeline
Sabirnetug clinical profile and differentiation
Biomarkers as treatment monitoring tools
Net income
−$28.80M
Diluted EPS
$-0.48
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call
Net income
−$37.15M*
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Confident tone
Sabirnetug clinical development
ARIA safety profile
Enrollment progress and site activation
Net income
−$29.77M
Diluted EPS
$-0.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Confident tone
ALTITUDE-AD Phase 2 enrollment and execution
Biomarker strategy (pTau217, synaptic markers)
Competitive landscape and field validation
Net income
−$20.54M
Diluted EPS
$-0.34
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Confident tone
Sabirnetug Clinical Profile and Differentiation
Subcutaneous Formulation
ALTITUDE-AD Phase II Trial
Net income
−$14.87M
Diluted EPS
$-0.25
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript
Confident tone
Phase 1 INTERCEPT-AD results
Sabirnetug (ACU193) drug profile
Phase 2 ALTITUDE-AD study
Net income
−$16.50M*
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript
Net income
−$12.96M
Diluted EPS
$-0.24
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Call Transcript
Net income
−$11.61M
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript
Net income
−$11.31M
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript
Net income
−$12.87M*
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2022 Earnings Call Transcript
Net income
−$10.71M
Diluted EPS
$-0.26
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript
Net income
−$10.15M
Diluted EPS
$-0.25
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript
Net income
−$9.13M
Diluted EPS
$-0.23
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript
Net income
−$8.35M*
Audio
Transcript
Slides
8-K10-K
Showing 1–24 of 24 webcasts
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
103 filings
89 filers
Visit website
Investor relations